COLOFIT: a consensus statement to support implementation
Endorsed by:
BSG
Association for Laboratory Medicine
The Association of Coloproctology of Great Britain and Ireland
Institute of Biomedical Science
The Royal College of General Practioners
The Primary Care Society for Gastroenterologists
SCOPE
This guidance is for all patients with NICE NG12 symptoms of possible colorectal cancer excluding those with an anal or rectal mass/ulceration who should be referred on a lower gastrointestinal (LGI) Urgent Suspected Cancer (USC) pathway immediately.
This guidance should be used in place of existing NICE DG56/NICE NG12 guidance for the use of the faecal immunochemical test for haemoglobin (FIT) in the lower GI urgent suspected cancer pathway. This guidance suggests a faecal haemoglobin (f-Hb) of≥10µg haemoglobin /gram faeces (µg/g) measured with a faecal immunochemical test (FIT) should be replaced with a COLOFIT ≥1% for referral to the Lower GI Urgent Suspected Cancer pathway. This threshold will be reviewed over time and may increase in future.
The Consensus Statement to support implementation can be read in full along with more information about the validation, implementation, target populations and referral pathways.